SCHEDULE 13D: Acorn Bioventures and Anders Hove Disclose Significant Stake in OnKure Therapeutics, Affirming Investment Intent

Investment firms Acorn Bioventures and its affiliates, along with manager Anders Hove, have disclosed a substantial beneficial ownership stake in OnKure Therapeutics, Inc., primarily for investment purposes.

Summary

• Acorn Bioventures, L.P., Acorn Capital Advisors GP, LLC, Acorn Bioventures 2, L.P., Acorn Capital Advisors GP 2, LLC, and Anders Hove (collectively, the "Reporting Persons") have filed a Schedule 13D disclosing their beneficial ownership in OnKure Therapeutics, Inc.
• Anders Hove, as an individual and manager of the general partners for the Acorn funds, beneficially owns 2,839,674 shares, representing 22.1% of OnKure Therapeutics' common stock.
• Acorn Bioventures, L.P. and its general partner beneficially own 1,709,944 shares, representing 13.3% of the common stock.
• Acorn Bioventures 2, L.P. and its general partner beneficially own 1,129,730 shares, representing 8.8% of the common stock.
• The shares were acquired solely for investment purposes, and the Reporting Persons currently have no present plans or proposals to change the Issuer's business, policies, management, structure, or capitalization.
• On October 4, 2024, OnKure Therapeutics, Inc. (formerly Reneo Pharmaceuticals, Inc.) consummated a merger with OnKure, Inc., where securities of Legacy OnKure held by Acorn were converted into 1,439,674 shares of the Issuer's Common Stock.
• On May 15, 2025, Acorn and Acorn 2 acquired an additional 1,400,000 shares (270,270 and 1,129,730 shares respectively) in an open market block purchase at $8.15 per share, totaling $11,410,000, using working capital.
• The percentages of ownership are based on 12,823,872 shares of Common Stock outstanding as of May 5, 2025, as reported in the Issuer's Form 10-Q filed on May 6, 2025.
• Isaac Manke, an affiliate of the Reporting Persons, serves on the board of directors of OnKure Therapeutics, Inc., with policies in place to prevent the misuse of material nonpublic information.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While it's a routine disclosure, the significant investment by a specialized biotech fund and the stated 'investment purposes' without immediate disruptive plans suggest confidence in the company. The boilerplate 'reserve the right' language for future actions introduces a slight element of uncertainty, preventing a higher score.

Positives

• The Reporting Persons state their acquisition is solely for investment purposes, indicating a long-term interest in the company's value.
• There are no present plans to disrupt the Issuer's business, policies, management, structure, or capitalization, suggesting stability for current operations.
• The significant stake held by experienced biotechnology investors like Acorn Bioventures and Anders Hove could be seen as a vote of confidence in OnKure Therapeutics' future.

Negatives

• None explicitly stated in the document regarding the company's performance or outlook.

Risks

• While currently for investment purposes, the Reporting Persons reserve the right to acquire or dispose of additional securities, which could impact stock price volatility.
• The Reporting Persons explicitly reserve the right to consider various alternative courses of action, including extraordinary corporate transactions (merger, reorganization, liquidation), sale of material assets, changes in the board or management, material changes in capitalization or dividend policy, or actions that may impede acquisition of control, which could introduce uncertainty.
• A significant concentration of ownership (Anders Hove at 22.1%) could allow for substantial influence over corporate decisions in the future, even if not currently planned.

Future Outlook

The Reporting Persons acquired their stake solely for investment purposes and currently have no plans to change the Issuer's business, policies, management, structure, or capitalization. However, they reserve the right to acquire or dispose of additional securities and may consider various alternative courses of action in the future, including significant corporate transactions or changes to the Issuer's governance, based on ongoing review of the Issuer's performance and market conditions.

Management Comments

• "The shares of Common Stock reported herein were acquired solely for investment purposes."
• "None of the Reporting Persons have any present plans or proposals that relate to or would result in any change in the business, policies, management, structure or capitalization of the Issuer."
• "The Reporting Persons reserve the right to acquire, or dispose of, additional securities of the Issuer in the ordinary course of their business, to the extent deemed advisable in light of their general investment and trading policies, market conditions or other factors."
• "The Reporting Persons have established policies and procedures to ensure that (i) material nonpublic information concerning the Issuer is not obtained by the Reporting Persons from Mr. Manke and (ii) Mr. Manke does not participate in or make investment decisions on behalf of the Reporting Persons with respect to the Reporting Persons investment in the Issuer's Common Stock."

Industry Context

This filing reflects a significant investment by a biotechnology-focused investment firm in a publicly traded biotechnology company, consistent with the trend of specialized funds taking substantial positions in promising life sciences ventures. The merger activity mentioned (Reneo Pharmaceuticals and OnKure, Inc.) is also common in the dynamic biotechnology sector, where companies often combine to leverage synergies or advance pipelines.

Comparison to Industry Standards

• This is a standard Schedule 13D filing, indicating a beneficial ownership stake exceeding 5%, which is a common threshold for disclosure in the U.S. market.
• The stated 'solely for investment purposes' intent is typical for initial 13D filings by institutional investors, distinguishing them from activist investors who might immediately propose changes.
• The acquisition of shares through open market block purchases is a common method for institutional investors to build significant positions efficiently.

Stakeholder Impact

• Shareholders: Increased institutional ownership may provide stability or signal confidence, but the potential for future activist actions (though not currently planned) could introduce uncertainty.
• Management: The current management team is affirmed by the 'no present plans' statement, but the Reporting Persons' reserved right to consider future changes could imply potential oversight or influence.
• Employees: No direct impact mentioned, but any future strategic changes considered by the Reporting Persons could indirectly affect employees.
• Customers/Suppliers: No direct impact mentioned.

Next Steps

• The Reporting Persons intend to review their investment in OnKure Therapeutics from time to time based on various factors, including the Issuer's business, financial condition, and market conditions.
• The Reporting Persons reserve the right to acquire or dispose of additional securities of the Issuer in the ordinary course of their business.
• The Reporting Persons may engage in discussions with other stockholders regarding the acquisition of additional shares.
• The Reporting Persons may consider the feasibility of various alternative courses of action with respect to their investment, including extraordinary corporate transactions or changes to the Issuer's structure, though no such plans are currently in place.

Key Dates

Keywords

OnKure Therapeutics, Schedule 13D, Acorn Bioventures, Anders Hove, Beneficial Ownership, Biotechnology Investment, SEC Filing, Investment Firm, Common Stock, Share Acquisition